SER Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Serina Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerSER

Market Cap26.6M

Cash RunwayRunway > 12 months

Next Catalyst2026-12-08

Public Research Snapshot

Serina Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Cobimetinib in Melanoma (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
intravenous (IV) recombinant human tissue plasminogen activator (rtPA)	Ischemic Stroke	n/a	Phase4	Public pipeline row
mRNA-1645-eODGT8	HIV Infections	Mrna	Phase 1	Public pipeline row
Recombinant tissue plasminogen activator (rt-PA)	Pulmonary Thromboembolisms \| Pulmonary Embolism	n/a	Phase4	Public pipeline row
Cobimetinib	Melanoma	n/a	Phase 3	Public pipeline row
Tenecteplase	THROMBOLYSIS	n/a	Phase 3	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2026-12-08	mRNA-1645-eODGT8	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01531829	Phase4	UNKNOWN	460	2012-07
NCT01429350	Phase4	COMPLETED	108	2016-10
NCT02427893	Phase 3	WITHDRAWN	n/a	2016-11
NCT03785678	Phase 3	COMPLETED	458	2023-02-28
NCT06694753	Phase 1	RECRUITING	96	2026-12-08

Scientific Context

literature_publication | REMOVED: Physicochemical properties of the potent influenza neuraminidase inhibitor, peramivir (BCX-1812).
asset_name | Cobimetinib
clinical_stage | Phase 3
clinical_stage | Phase 3
indication | Melanoma

Want the full SER research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.